

PRODUCT MONOGRAPH

Pr Diltiazem Hydrochloride Injection

Diltiazem Hydrochloride

5 mg / mL

Antiarrhythmic

Date of Preparation:
September 14, 2022

Auro Pharma Inc.

3700 Steeles Avenue West, Suite # 402
Woodbridge, Ontario, L4L 8K8
CANADA

Submission Control Number: 252505

PRODUCT MONOGRAPH

Pr **Diltiazem Hydrochloride Injection**

5mg/mL

THERAPEUTIC CLASSIFICATION

Antiarrhythmic

ACTION AND CLINICAL PHARMACOLOGY

Mechanism of Action: Diltiazem Hydrochloride Injection inhibits the influx of calcium and ions during membrane depolarisation of cardiac and vascular smooth muscle. The therapeutic benefits of diltiazem in supraventricular tachycardias are related to its ability to slow atrioventricular (AV) nodal conduction time and prolong AV nodal refractoriness. Diltiazem exhibits frequency (use) dependent effects on AV nodal conduction such that it may selectively reduce the heart rate during tachycardias involving the AV node with little or no effect on normal AV nodal conduction at normal heart rates.

Diltiazem slows the ventricular rate in patients with a rapid ventricular response during atrial fibrillation or atrial flutter (AF/FL). Diltiazem converts paroxysmal supraventricular tachycardia (PSVT) to normal sinus rhythm by interrupting the re- entry circuit in AV nodal re-entrant tachycardias and reciprocating tachycardias, e.g. Wolff-Parkinson-White syndrome (WPW).

Diltiazem prolongs the sinus cycle length. It has no effects on the sinus node recovery time or on the sinoatrial (SA) conduction time in patients without SA nodal dysfunction. Diltiazem has no significant electrophysiologic effects on tissues in the heart that are fast sodium channel dependent, e.g. His-Purkinje tissue, atrial and ventricular muscle and extranodal accessory pathways.

Like other calcium channel antagonists, because of its effect on vascular smooth muscle, Diltiazem decreases total peripheral resistance resulting in a decrease in both systolic and diastolic blood pressure.

Hemodynamics: In patients with cardiovascular disease, diltiazem hydrochloride administered intravenously in single bolus doses, followed in some cases by a continuous infusion, reduced blood pressure, systemic vascular resistance, the rate-pressure product, and coronary vascular resistance and increased coronary blood flow. Following administration of one or two

intravenous bolus doses of Diltiazem Hydrochloride Injection, response usually occurs within 3 minutes and maximal heart rate reduction generally occurs in 2 to 7 minutes. Heart rate reduction may last from 1 to 3 hours. Upon discontinuation of infusion, heart rate reduction may last from 0.5 hours to more than 10 hours (median duration= 7 hours). Hypotension, if it occurs, may be similarly persistent.

In a limited number of studies of patients with compromised myocardiums (severe congestive heart failure, acute myocardial infarction, hypertrophic cardiomyopathy), administration of intravenous diltiazem produced no significant effect on contractility, left ventricular and diastolic pressure, or pulmonary capillary wedge pressure. The mean ejection fraction and cardiac output/index remained unchanged or increased. Maximal hemodynamic effects usually occurred within 2 to 5 minutes of an injection. However, in rare instances, worsening of congestive heart failure has been reported in patients with pre-existing impaired ventricular function.

Pharmacodynamics: The prolongation of PR interval correlated significantly with plasma diltiazem concentration in normal volunteers using the Sigmoidal E_{max} model. Changes in heart rate, systolic blood pressure, and diastolic blood pressure did not correlate with diltiazem plasma concentrations in normal volunteers. Reduction in mean arterial pressure correlated linearly with diltiazem plasma concentration in a group of hypertensive patients.

In patients with atrial fibrillation and atrial flutter, a significant correlation was observed between the percent reduction in HR and plasma diltiazem concentration using the Sigmoidal E_{max} model. Based on this relationship, the mean plasma diltiazem concentration required to produce a 20% decrease in heart rate was determined to be 80 ng/mL. Mean plasma diltiazem concentrations of 130 ng/mL and 300 ng/mL were determined to produce reductions in heart rate of 30% and 40%, respectively.

Pharmacokinetics: Following a single intravenous injection in healthy male volunteers, diltiazem appears to obey linear pharmacokinetics over a dose range of 10.5 to 21.0 mg. The plasma elimination half-life is approximately 3.4 hours. The apparent volume of distribution of diltiazem is approximately 305 L. Diltiazem is extensively metabolised in the liver with a systemic clearance of approximately 65 L/hr.

After constant rate intravenous infusion to healthy male volunteers, diltiazem exhibits nonlinear pharmacokinetics over an infusion range of 4.8 to 13.2 mg/hr for 24 hours. Over this infusion range, as the dose is increased, systemic clearance decreases from 64 to 48 L/hr while the plasma elimination half-life increases from 4.1 to 4.9 hours. The apparent volume of distribution remains unchanged (360 - 391 L).

In patients with AF/FL, diltiazem systemic clearance has been found to be decreased compared to healthy volunteers. In patients administered bolus doses ranging from 2.5 mg to 38.5 mg, systemic clearance averaged 36 L/hr. In patients administered continuous infusions at 10 mg/hr or 15 mg/hr for 24 hours, diltiazem systemic clearance averaged 42 L/hr and 31 L/hr, respectively.

The metabolic pathways of Diltiazem metabolism include N- and O-demethylation (via

cytochrome P-450), deacetylation (via plasma and tissue esterases), in addition to conjugation (via sulfation and glucuronidation). In vitro studies have demonstrated that CYP 3A4 is the principal CYP isoenzyme involved in N-demethylation. Metabolites N-monodesmethyldiltiazem, desacetyldiltiazem, desacetyl-N-monodesmethyldiltiazem, desacetyl-0-desmethyldiltiazem, and desacetyl-N, 0-desmethyldiltiazem have been identified in human urine following oral administration. With oral administration 2% to 4% of the unchanged diltiazem appears in the urine. Drugs which induce or inhibit hepatic microsomal enzymes may alter diltiazem disposition.

Following single intravenous injection of diltiazem hydrochloride, however, plasma concentrations of N-monodesmethyldiltiazem and desacetyldiltiazem, two principal metabolites found in plasma after oral administration, are typically not detected. These metabolites are observed, however, following 24 hour constant rate intravenous infusion. Total radioactivity measurement following short intravenous administration in healthy volunteers suggests the presence of other unidentified metabolites which attain higher concentrations than those of diltiazem and are more slowly eliminated. Plasma half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.

Diltiazem is 70% to 80% bound to plasma proteins.

INDICATIONS AND CLINICAL USE

Diltiazem Hydrochloride Injection is indicated for the following:

- 1. Atrial Fibrillation or Atrial Flutter.** Temporary control of rapid ventricular rate in atrial fibrillation or atrial flutter. It should not be used in patients with AF/FL associated with an accessory bypass tract such as in Wolff-Parkinson-White (WPW) syndrome, or short PR syndrome, e.g. Lown-Ganong-Levine syndrome. Diltiazem Hydrochloride Injection rarely converts atrial fibrillation or atrial flutter to normal sinus rhythm.
- 2. Paroxysmal Supra-ventricular Tachycardia.** Rapid conversion of paroxysmal supraventricular tachycardias to sinus rhythm. This includes AV nodal re-entrant tachycardias and reciprocating tachycardias associated with an extra-nodal accessory pathway, such as the WPW syndrome, or short PR syndrome, e.g. Lown-Ganong-Levine syndrome. Unless otherwise contraindicated, appropriate vagal maneuvers should be attempted prior to administration of Diltiazem Hydrochloride Injection.

The use of Diltiazem Hydrochloride Injection for control of ventricular response **in** patients with atrial fibrillation or atrial flutter or conversion to sinus rhythm in patients with paroxysmal supraventricular tachycardia should be undertaken with caution when the patient is compromised hemodynamically or is taking other drugs that decrease any or all of the following; peripheral resistance, myocardial filling, myocardial contractility, or electrical impulse propagation in the myocardium.

For either indication the setting should include continuous monitoring of the ECG and

frequent measurement of blood pressure. A defibrillator and emergency equipment should be readily available.

CONTRAINDICATIONS

Diltiazem Hydrochloride Injection is contraindicated:

1. In patients with sick sinus syndrome except in the presence of a functioning ventricular pacemaker.
2. In patients with second-or third-degree AV block except in the presence of a functioning ventricular pacemaker.
3. In patients with known hypersensitivity to diltiazem.
4. In patients with severe hypotension or cardiogenic shock.
5. In patients with AF/FL associated with an accessory bypass tract such as in WPW syndrome, or short PR syndrome, e.g. Lown-Ganong-Levine syndrome. As with other agents which slow AV nodal conduction and do not prolong the refractoriness of the accessory pathway (e.g. verapamil, digoxin), in rare instances patients with AF/FL associated with an accessory bypass tract may experience a potentially life-threatening increase in heart rate accompanied by hypotension when treated with Diltiazem Hydrochloride Injection.
6. In patients with ventricular tachycardia. Administration of other calcium channel blockers to patients with wide complex tachycardia (QRS > 0.12 seconds) has resulted in hemodynamic deterioration and ventricular fibrillation. It is important that an accurate pre-treatment diagnosis distinguish wide complex QRS tachycardia of supra-ventricular origin from that of ventricular origin prior to administration of Diltiazem Hydrochloride Injection.
7. In pregnancy and in women of childbearing potential. Fetal malformations and adverse effects on pregnancy have been reported in animals. In repeated dose studies, a high incidence of vertebral column malformations was present in the offspring of mice receiving more than 50 mg/kg of diltiazem HCl orally.

In the offspring of mice receiving a single oral dose of 50 or 100 mg/kg on day 12 of gestation, the incidence of cleft palate and malformed extremities was significantly higher. Vertebral malformations were most prevalent when they received the drug on day 9. In rats, a significantly higher fetal death rate was present when 200 and 400 mg/kg were given orally on days 9 to 14 of gestation. Single oral dose studies in rats resulted in a significant incidence of skeletal malformations in the offspring of the group receiving 400 mg/kg on day 11. In rabbits, all pregnant dams receiving 70 mg/kg orally from day 6-18 of gestation aborted; at 35 mg/kg, a significant increase in skeletal malformations was recorded in the offspring (see

REPRODUCTION STUDIES).

8. **Intravenous** diltiazem and **intravenous** beta-blockers should not be administered together or in close proximity (within a few hours).

WARNINGS

Cardiac Conduction: Diltiazem Hydrochloride Injection prolongs AV nodal conduction and refractoriness that may rarely result in second or third-degree AV block in sinus rhythm. Concomitant use of diltiazem with agents known to affect cardiac conduction (such as beta blockers, digitalis, or amiodarone) may result in additive effects (see **PRECAUTIONS**, Drug Interactions). If high-degree AV block occurs in sinus rhythm, intravenous diltiazem should be discontinued and appropriate supportive measures instituted (see **SYMPTOMS AND TREATMENT OF OVERDOSAGE**).

Congestive Heart Failure: Although diltiazem has a negative inotropic effect in isolated animal tissue preparations, hemodynamic studies in humans with normal ventricular function and in patients with a compromised myocardium, such as severe CHF, acute MI, and hypertrophic cardiomyopathy, have not shown a reduction in cardiac index nor consistent negative effects on contractility (dp/dt). Administration of **oral** diltiazem is contraindicated in myocardial infarction patients who have left ventricular failure manifested by pulmonary congestion. Experience with the use of Diltiazem Hydrochloride Injection in patients with impaired ventricular function is limited. Caution should be exercised when using the drug in such patients.

Hypotension: Decreases in blood pressure associated with Diltiazem Hydrochloride Injection therapy may occasionally result in symptomatic hypotension (see **ADVERSE REACTIONS**). In controlled clinical trials, 3.2% of patients required some form of intervention (use of intravenous fluids, or the Trendelenburg position) for blood pressure support following Diltiazem Hydrochloride Injection. The use of intravenous diltiazem for control of ventricular response in patients with supra-ventricular arrhythmias should be undertaken with caution when the patient is compromised hemodynamically. In addition, caution should be used in patients taking other drugs that decrease peripheral resistance, intravascular volume, myocardial contractility or conduction.

Acute Hepatic injury: In rare instances, significant elevations of enzymes such as alkaline phosphatase, LDH, SGOT, SGPT, and symptoms consistent with acute hepatic injury have been noted following oral diltiazem. Although a causal relationship to diltiazem has not been established in all cases, a drug induces hypersensitivity reaction is suspected (see **ADVERSE REACTIONS**). Therefore, the potential for acute hepatic injury exists following administration of intravenous diltiazem.

Ventricular Premature Beats (VPBs): VPBs may be present on conversion of PSVT to sinus rhythm with intravenous diltiazem. These VPBs are transient, are typically considered to be benign and appear to have no clinical significance. Similar ventricular complexes have been noted during cardioversion, other pharmacologic therapy, and during spontaneous conversion of PSVT to sinus rhythm.

PRECAUTIONS

Dermatologic Events: Dermatologic events (see ADVERSE REACTIONS) may be transient and may disappear despite continued use of diltiazem. Dermatologic events progressing to erythema multiforme and/or exfoliative dermatitis have been infrequently reported following oral diltiazem (see ADVERSE REACTIONS). Therefore the potential for these dermatologic reactions exists following exposure to intravenous diltiazem. Should a dermatologic reaction persist, the drug should be discontinued.

Impaired Hepatic or Renal Function: Diltiazem is extensively metabolised by the liver and excreted by the kidneys and in bile. The drug should be used with caution in patients with impaired renal or hepatic function. The monitoring of laboratory parameters of renal or hepatic function is recommended. Liver cirrhosis was shown to reduce apparent oral diltiazem clearance, prolong the half-life of orally administered diltiazem and increase its bioavailability by 69%.

In subacute and chronic dog and rat studies designed to produce toxicity, high oral doses of diltiazem were associated with hepatic damage. In special subacute hepatic studies, oral doses of 125 mg/kg and higher in rats were associated with histological changes in the liver, which were reversible when the drug was discontinued. In dogs, oral doses of 20 mg/kg were also associated with hepatic changes; however, these changes were reversible with continued dosing.

Nursing Mothers: Diltiazem has been reported to be excreted in human milk. One report with oral diltiazem suggests that concentrations in breast milk may approximate serum levels. Since diltiazem's safety in newborns has not been established, it should not be given to nursing mothers.

Pediatric Use: Safety and effectiveness in children have not been established.

Drug Interactions: Due to potential for additive effects, caution is warranted in patients receiving Diltiazem Hydrochloride Injection concomitantly with any agent(s) known to affect cardiac contractility and/or SA or AV node conduction (see WARNINGS).

Cytochrome P450 System: As with all drugs, care should be exercised when treating patients with multiple medications. Calcium channel blockers undergo biotransformation by the cytochrome P450 system. Coadministration of diltiazem with other drugs which follow the same route of biotransformation may result in altered bioavailability. Dosages of similarly metabolised drugs, particularly those of low therapeutic ratio, and especially in patients with renal and/or hepatic impairment, may require adjustment when starting or stopping concomitantly administered diltiazem to maintain optimum therapeutic blood levels.

Drugs known to be inhibitors of the cytochrome P450 system include: azole antifungals, cimetidine, cyclosporine, erythromycin, quinidine, warfarin.

Drugs known to be inducers of the cytochrome P450 system include: phenobarbital, phenytoin, rifampin.

Drugs known to be biotransformed via P450 include: benzodiazepines, flecainide, imipramine,

propafenone, terfenadine, theophylline.

Amiodarone: Severe conduction system abnormalities including heart block of varying degree, sinus arrest and low cardiac output state of life threatening severity have been reported following concomitant use of diltiazem and amiodarone. These drugs may also have additive effects on cardiac conduction and contractility.

Anesthetics: The depression of cardiac contractility, conductivity, and automaticity as well as the vascular dilation associated with anesthetics may be potentiated by calcium channel blockers. When used concomitantly, anesthetics and calcium blockers should be titrated carefully.

Benzodiazepines: Diltiazem significantly increases peak plasma levels and the elimination half-life of triazolam and midazolam.

Beta-Blockers: Intravenous diltiazem has been administered to patients on chronic oral beta-blocker therapy. The combination of the two drugs was generally well tolerated without serious adverse effects. If intravenous diltiazem is administered to patients receiving chronic oral beta-blocker therapy, the possibility for bradycardia, AV block and/or depression of contractility should be considered (see **CONTRAINDICATIONS**).

Oral administration of diltiazem with propranolol in five normal volunteers resulted in increased propranolol levels in all subjects and bioavailability of propranolol was increased approximately 50%. In vitro, propranolol appears to be displaced from its binding sites by diltiazem.

Calcium Antagonists: Limited clinical experience suggests that in certain severe conditions not responding adequately to verapamil or to nifedipine, using diltiazem in conjunction with either of these drugs may be beneficial.

Carbamazepine: Concomitant administration of oral diltiazem with carbamazepine has been reported to result in elevated serum levels of carbamazepine (40% to 72% increase) resulting in toxicity in some cases. Patients receiving these drugs concurrently should be monitored for a potential drug interaction.

Cimetidine: A study in six healthy volunteers has shown a significant increase in peak diltiazem plasma levels (58%) and area-under-the-curve (53%) after a 1-week course of cimetidine at 1,200 mg per day and a single dose of oral diltiazem 60 mg. Ranitidine produced smaller, non-significant increases. Patients currently receiving diltiazem therapy should be carefully monitored for a change in pharmacological effect when initiating and discontinuing therapy with cimetidine. An adjustment in the diltiazem dose may be warranted.

Cyclosporine: A pharmacokinetic interaction between diltiazem and cyclosporine has been observed during studies involving renal and cardiac transplant patients. In renal and cardiac transplant recipients, a reduction of cyclosporine dose ranging from 15% to 48% was necessary to maintain cyclosporine through concentrations similar to those seen prior to the addition of diltiazem. If these agents are to be administered concurrently, cyclosporine concentrations should be monitored, especially when diltiazem therapy is initiated, adjusted or discontinued. The effect

of cyclosporine on diltiazem plasma concentrations has not been evaluated.

Digitalis: Intravenous diltiazem has been administered to patients receiving either intravenous or oral digitalis therapy. The combination of the two drugs was well tolerated without serious adverse effects. However, since both drugs affect AV nodal conduction, patients should be monitored for excessive slowing of the heart rate and/or AV block.

Lovastatin: In a ten-subject study, coadministration of diltiazem (120 mg bid, diltiazem SR) with lovastatin resulted in a 3-4 times increase in mean lovastatin AUC and C_{max} , versus lovastatin alone; no change in pravastatin AUC and C_{max} was observed during diltiazem coadministration. Diltiazem plasma levels were not significantly affected by lovastatin or pravastatin.

Rifampin: Administration of diltiazem with rifampin markedly reduced plasma diltiazem concentrations and the therapeutic effect of diltiazem.

Short and Long-acting Nitrates: Diltiazem may be safely co-administered with nitrates, but there have been few controlled studies to evaluate the antianginal effectiveness of this combination.

ADVERSE REACTIONS

Adverse reactions were derived from controlled clinical trials in 411 patients with paroxysmal supra-ventricular tachycardia, atrial fibrillation, or atrial flutter. Adverse reactions were reported in 17.3% of patients on diltiazem hydrochloride, and required discontinuation of treatment in 1.5% of patients.

World wide experience in over 1,300 patients was similar.

The most common adverse reactions (incidence of at least 1%) were: hypotension 7.5%, symptomatic hypotension 3.2%, injection site reaction (e.g. itching, burning) 3.9%, vasodilation (flushing) 1.7%, and arrhythmia (junctional rhythm or isorhythmic dissociation) 1.0%.

In addition, the following events were reported in less than 1% of clinical trials or during post marketing-surveillance cases:

Cardiovascular: Atrial flutter, first degree AV block, second degree AV block, bradycardia, chest pain, congestive heart failure, sinus pause, sinus node dysfunction, syncope, ventricular arrhythmia, ventricular fibrillation, ventricular tachycardia.

Dermatologic: Pruritus, sweating.

Gastrointestinal: Constipation, elevated SGOT, SGPT or alkaline phosphatase (see WARNINGS), nausea, vomiting.

Nervous system: Dizziness, paresthesia.

Other: Amblyopia, asthenia, dry mouth, dyspnea, general edema, headache, hyperuricemia.

Although not observed in clinical trial with diltiazem hydrochloride, other reactions associated with oral diltiazem have been reported.

Cardiovascular: Third degree AV block, bundle branch block, ECG abnormality, palpitations, syncope, tachycardia, ventricular extrasystoles.

Dermatologic: Alopecia, acute generalised exanthematous pustulosis, erythema multiforme (Stevens-Johnson syndrome, toxic epidermal necrolysis), exfoliative dermatitis (see PRECAUTIONS), generalised rash some characterised as leukocytoclastic vasculitis, petechiae, photosensitivity, purpura, rash, urticaria.

Gastrointestinal: Anorexia, diarrhea, dysgeusia, dyspepsia, elevations of SGPT and LDH (see WARNINGS), thirst, weight increase.

Nervous system: Abnormal dreams, amnesia, depression, extrapyramidal symptoms, gait abnormality, hallucinations, insomnia, nervousness, personality change, somnolence, tremor.

Other: CPK elevation, detached retina, epistaxis, eye irritation, gingival hyperplasia, hemolytic anemia, hyperglycemia, impotence, increased bleeding time, leukopenia, muscle cramps, nasal congestion, nocturia, osteoarticular pain, polyuria, retinopathy, sexual difficulties, thrombocytopenia, tinnitus.

Events such as myocardial infarction have been observed which are not readily distinguishable from the natural history of the disease for the patient.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

SYMPTOMS AND TREATMENT OF OVERDOSAGE

Overdosage experience is limited. In the event of overdosage or an exaggerated response, appropriate supportive measures should be employed. The following measures may be considered:

Bradycardia: Administer atropine (0.60 to 1.0 mg). If there is no response to vagal blockade administer isoproterenol cautiously.

High-degree AV block: Treat as for bradycardia above. Fixed high-degree AV block should be treated with cardiac pacing.

Cardiac failure: Administer inotropic agents (isoproterenol, dopamine, or dobutamine) and diuretics.

Hypotension: Vasopressors (e.g. dopamine or norepinephrine).

The effectiveness of intravenous calcium administration to reverse the pharmacological effects of diltiazem overdose has been inconsistent. In a few reported cases, overdose with calcium channel blockers associated with hypotension and bradycardia that was initially refractory to atropine became more responsive to atropine after the patients received intravenous calcium. In some cases intravenous calcium has been administered (1 g calcium chloride or 3 g calcium gluconate) over 5 minutes, and repeated every 10-20 minutes as necessary. Calcium gluconate has also been administered as a continuous infusion at a rate of 2 g per hour for 10 hours. Infusions of calcium for 24 hours or more may be required. Patients should be monitored for signs of hypercalcemia.

Actual treatment and dosage should depend on the severity of the clinical situation and the judgement and experience of the treating physician.

The intravenous LD₅₀'s in mice and rats were 58-61 and 38-39 mg/kg, respectively. The toxic dose in man is not known.

For management of a suspected drug overdose, contact your regional poison control centre.

DOSAGE AND ADMINISTRATION

Direct Intravenous Single Injections (Bolus) The initial dose of Diltiazem Hydrochloride Injection should be 0.25 mg/kg body weight as a bolus administered over 2 minutes. If response is inadequate, a second dose may be administered after 15 minutes. The second bolus dose of Diltiazem Hydrochloride Injection should be 0.35 mg/kg body weight administered over two minutes. Subsequent intravenous bolus doses should be individualised for each patient. Some patients may respond to an initial dose of 0.15 mg/kg, although duration of action may be shorter.

Continuous Intravenous Infusion: For continued reduction of the heart rate (up to 24 hours) in patients with AF/FL, an intravenous infusion of Diltiazem Hydrochloride Injection may be administered. Immediately following bolus administration of 0.25 mg/kg or 0.35 mg/kg Diltiazem Hydrochloride Injection, and reduction in heart rate, begin an intravenous infusion of Diltiazem Hydrochloride Injection. The recommended initial infusion rate of Diltiazem Hydrochloride Injection is 10 mg/hr. The infusion rate may be increased 5 mg/hr to 15 mg/hr as needed, if further reduction in heart rate is required. Some patients may maintain response to an initial rate of 5 mg/hr. The infusion may be maintained for up to 24 hours.

Diltiazem shows dose-dependent, non-linear pharmacokinetics during continuous intravenous infusion. Duration of infusion longer than 24 hours and infusion rates greater than 15 mg/hr have not been studied. Therefore, infusion duration exceeding 24 hours and infusion rates exceeding 15 mg/hr are not recommended.

Transition to Further Antiarrhythmic Therapy: Experience in the use of antiarrhythmic agents following Diltiazem Hydrochloride Injection is limited. In controlled clinical trials, therapy with antiarrhythmic agents to maintain reduced heart rate in atrial fibrillation or atrial flutter, or for prophylaxis of paroxysmal supra-ventricular tachycardia was generally started within three hours after bolus administration. Patients should be dosed on an individual basis and reference should be made to the respective manufacturer's product monograph for information relative to dosage and administration of antiarrhythmic agents.

PHARMACEUTICAL INFORMATION


DRUG SUBSTANCE

Proper Name: Diltiazem Hydrochloride

Chemical Name: Hydrochloride of (2S,3S)-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate.

(+)-5-[2-(Dimethylamino)ethyl]-cis-2,3-dihydro-3-hydroxy - 2-(p-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one acetate(ester) monohydrochloride.

Structural Formula:



Molecular Formula: $C_{22}H_{26}N_2O_4S.HCl$

Molecular Weight: 451.0 g / mol

Appearance: White or almost white, crystalline powder

Solubility profile: Freely soluble in water, in methanol and in methylene chloride, slightly soluble in anhydrous ethanol

PREPARATION OF IV SOLUTION

Dilution for Continuous Intravenous Infusion: To prepare Diltiazem Hydrochloride Injection for continuous intravenous infusion, aseptically transfer the appropriate quantity (see chart) of Diltiazem Hydrochloride Injection to the desired volume of either Sodium Chloride Injection USP 0.9% or Dextrose Injection USP 5%. Mix thoroughly. Use within 24 hours.

Diluent Volume	Quantity of Diltiazem Hydrochloride Injection	Final Concentration	Administration	
			Dose Infusion Rate	
100 mL	125 mg (25 mL)	1.0 mg/mL	5 mg/hr*	5 mL/hr
			10 mg/hr	10 mL/hr
			15 mg/hr	15 mL/hr
250 mL	250 mg (50 mL)	0.83 mg/mL	5 mg/hr*	6 mL/hr
			10 mg/hr	12 mL/hr
			15 mg/hr	18 mL/hr
500 mL	250 mg (50 mL)	0.45 mg/mL	5 mg/hr*	11 mL/hr
			10 mg/hr	22 mL/hr
			15 mg/hr	33 mL/hr

* The recommended initial infusion rate of Diltiazem Hydrochloride Injection is 10 mg/hr. An infusion rate of 5 mg/hr may be appropriate for some patients.

Diltiazem Hydrochloride Injection was tested for compatibility with two commonly used intravenous fluids at a concentration range of 0.45 mg/mL to 1.0 mg/mL. Diltiazem Hydrochloride Injection was found to be physically compatible and chemically stable in Sodium Chloride Injection USP 0.9% or Dextrose Injection USP 5% for at least 24 hours when stored in glass or in polyvinylchloride (PVC) bags at a controlled room temperature of 15 °C to 30 °C under ambient light or under refrigeration at 2 °C to 8 °C.

Because of potential physical incompatibilities, Diltiazem Hydrochloride Injection should not be mixed with any other drugs in the same container. Physical incompatibilities (precipitate formation or cloudiness) were observed when Diltiazem Hydrochloride Injection was infused in the same intravenous line with the following drugs: acetazolamide, acyclovir, aminophylline, ampicillin, ampicillin sodium/sulbactam sodium, cefamandole, cefoperazone, diazepam, furosemide, hydrocortisone sodium succinate, insulin (regular; 100 units/mL), methylprednisolone sodium succinate, mezlocillin, nafcillin, phenytoin, rifampin, and sodium bicarbonate. Therefore, it is recommended that Diltiazem Hydrochloride Injection not be co-infused in the same intravenous line.

As with all parenteral drug products, intravenous admixtures should be inspected visually for

clarity, particulate matter, precipitation, discoloration and leakage prior to administration whenever solution and container permit.

STABILITY AND STORAGE RECOMMENDATION:

Store under refrigeration 2°C to 8°C. Protect from light. Do not freeze.

AVAILABILITY OF DOSAGE FORMS

Composition: Sorbitol solution 70%, Citric acid monohydrate, Sodium Citrate, Hydrochloric Acid and Sodium Hydroxide.

Diltiazem Hydrochloride Injection 5 mg/mL is available in 5 mL, 10 mL and 30 mL single-use glass vials, boxes of 5. **Discard unused portion.**

The vial stopper is not made with natural rubber latex.

PHARMACOLOGY

Animal Pharmacology: It has been demonstrated in animal studies that diltiazem slows conduction through the AV node and increases the refractory period of the AV node in a dose-dependent and plasma concentration-dependent manner. These electrophysiological effects on the AV node are the basis for the usefulness of diltiazem in the treatment of supra-ventricular tachyarrhythmias. The ability of diltiazem to prolong conduction time has been demonstrated in isolated perfused AV nodes and *in vivo*. In a study in normotensive dogs who received 0.01, 0.02, 0.04 or 0.08 mg/kg/min I.V. diltiazem for 30 minutes, these effects on the AV node occurred at slightly lower doses than the hypotensive or bradycardic (sino-atrial node) effects. Significant prolongation of AV nodal refractory periods was apparent at the 0.02 mg/kg/min dose, while hemodynamic variables were significantly altered only at doses of 0.04 and 0.08 mg/kg/min.

In anaesthetized dogs, diltiazem (400 µg/kg + 4.0 µg/kg/min I.V.) resulted in a 37% slowing of AV conduction. This dose of diltiazem produced mean plasma levels of 175 ng/mL. Similar results were obtained in separate study. Diltiazem (1.2 mg/kg I.V.) infused over 30 minutes resulted in a 50% increase in the A-I-I interval (or slowing of AV conduction) and an increase in the effective refractory period of the AV node.

A number of animal studies have investigated the antiarrhythmic effects of diltiazem on arrhythmias induced by cardiac ischemia. In the coronary occlusion model in dogs, ischemia-induced conduction impairment was improved by a diltiazem dose of 0.02 mg/kg/min I.V. for 30 minutes, resulting in less arrhythmias and ventricular fibrillation. The peak antiarrhythmic effect of diltiazem, when administered as an I.V. bolus dose of 0.1 mg/kg, occurred at approximately three minutes and persisted for five minutes.

Beneficial effects of diltiazem have also been demonstrated in the cat and in the pig. In cats where arrhythmias were induced by a combination of acute myocardial ischemia and sympathetic hyperactivity, 0.1 mg/kg plus 0.2 mg/kg/hour diltiazem injection abolished both ventricular tachycardia and fibrillation that had occurred in 64% and 36% of the control animals, respectively.

In pigs, ischemia-induced conduction disturbances following coronary artery occlusion were reduced in a dose- dependent manner by pre-treatment with diltiazem (0.01, 0.1, 0.3, or 1.0 mg/kg) started five minutes prior to occlusion.

TOXICOLOGY

Acute Toxicity

Route	Species	Sex	LD ₅₀ (mg/kg)	LD ₅₀ 95% Confidence Limits
oral	mouse	M&F	415-740	(343-852)
	rat	M&F	560-810	(460-1004)
s.c.	mouse	M&F	260-280	(220-307)
	rat	M&F	520-550	(452-672)
i.p.	mouse	M&F	187	(165-211)
	rat	M&F	211	(155-287)
i.v.	mouse	M&F	58-61	(52-69)
	rat	M&F	38-39	(34-44)

Diltiazem was also administered intravenously to dogs at doses ranging from 8 to 32 mg/kg. Dogs receiving 8 mg/kg exhibited decreased activity only, while the dog receiving 32 mg/kg died. Dogs receiving 12 mg/kg or more exhibited decreased activity, loss of righting reflex, convulsions, respiratory distress, and opisthotonos. The severity and duration of these findings were dose-related.

The toxic symptoms were similar in most species and consisted of decreased activity, prostration, urination, tonic and clonic convulsions, ataxia, loss of muscle tone, loss of righting reflex, and respiratory distress at high dosages. Symptoms occurred immediately after dosing, followed a dose response with regard to duration and severity, and disappeared within 24 hours.

Subacute Toxicity: Injectable diltiazem was administered intravenously to rats at dosage levels of 3, 6, and 18 mg/kg/day for 28 consecutive days. One female receiving 18 mg/kg/day died on day 27. No treatment-related abnormalities were noted during gross or histopathological examination. Transient electrocardiographic changes and convulsive episodes were observed in the 18 mg/kg/day group. Transient bradycardia and respiratory distress were noted in some animals treated with 6 and 18 mg/kg/day. No abnormalities were noted in animals treated with 3 mg/kg/day.

When injectable diltiazem was given intravenously to dogs twice daily at 0.5, 1.5, and 4.5 mg/kg for 28 consecutive days, the major clinical symptoms displayed ranged from decreased activity at 1.5 mg/kg BID to ataxia and collapse at 4.5 mg/kg BID. No abnormalities were noted during gross and histopathological examination. Examination of electrocardiographic recordings revealed AV nodal disturbances, which were dose-dependent in terms of degree and duration, and ranged from prolongation of PR interval to third degree AV block and junctional rhythms. Only the 4.5 mg/kg BID group exhibited the more severe symptoms.

Chronic Toxicity and Carcinogenicity: In mice, diltiazem was administered orally at doses of 5, 15, or 30 mg/kg/day for a period of 21 months in females. Because of a lower survival, males were terminated at 20 months. Gross and histopathological examination failed to reveal any treatment-related increase in the incidence of either neoplastic or other toxic lesions.

Rats received 6.25, 25 or 100 mg/kg/day of diltiazem orally for 24 months. An additional group received 200 mg/kg/day for 12 months. Treatment was terminated at 23 months in females receiving 100 mg/kg/day because of low survival. Females had increased weight gain at 100 and 200 mg/kg/day, and food consumption was increased among both sexes at these dose levels. Organ weight data revealed a significant increase in liver weight for rats of both sexes given 200 mg/kg/day. Microscopic evaluation revealed some evidence of dose-dependent hepatic cytoplasmic vacuolization in rats treated with doses of 100 and 200 mg/kg/day and killed at 12 months. At 24 months, there were similar findings in control and treated animals. There was no increase in the incidence of neoplastic or other toxic lesions in rats treated with diltiazem.

Diltiazem was administered orally to dogs for 12 months at doses of 5, 10, and 20 mg/kg/day. A dose-related suppression of body weight gain became noticeable after 6 months.

Mutagenicity: There was no mutagenic response *in vitro* or *in vivo* in mammalian cell assays or *in vitro* in bacterial assays.

Reproduction Studies

Results in Mice

Route	Doses (mg/kg)	Time of Administration During	Findings in the Offspring
Oral	10, 25, 50, 100, 200, 400	Days 7 to 12	High incidence of vertebral column malformations when more than 50 mg/kg was administered.
	Single dose of 12.5, 25, 50, 100, or 200	One of days 7 to 14	Cleft palate and malformation of extremities or trunk were significantly higher when 50 or 100 mg/kg was administered on day 12. Vertebral malformations were most prevalent when 50 or 100 mg/kg was administered on day 9.
Intra-peritoneal	0.2, 3.1, 6.3, 12.5, 25	Days 7 to 12	Fetal mortality greatly increased when 12.5mg/kg or more was administered. No teratogenic effect was demonstrated.
	Single dose of 3.1, 6.3, 12.5, 25, or 50	One of days 5 to 16	Brachydactyly and hematoma in the extremities when 50 mg/kg was administered on day 13. Vertebral column malformations from the thoracic to coccygeal level and malformations of the ribs were observed when a dose of 25 mg/kg or greater was administered on day 9.

Results in Rats

Route	Doses (mg/kg)	Time of Administration During Gestation	Findings in the Offspring

Oral	10, 50, 100, 200, 400	Days 9 to 14	No teratogenic effect. High fetal death rate when 200 and 400 mg/kg were administered.
	10, 30, 100	Days 6 to 15	No teratogenic effect.
	Single dose of 300, 400, or 600	One of days 9 to 14	Significant increase of skeletal malformations involving vertebrae and sternbrae when 400 mg/kg was administered on day 11. General edema, short or absent tail were observed when 600 mg/kg was administered on day 12.
Intra-peritoneal	0.2, 2.0, 20, 40, 80	Days 9 to 14	Brachydactyly and hematoma in the front paw and tail and a high fetal mortality rate were observed when 80 mg/kg was administered.
	80	Days 9 to 11	Vertebral anomalies.
	80	Days 12 to 14	Brachydactyly, hematoma of the front paw, tail deformities and high fetal mortality rate.
	Single dose of 80	One of days 9 to 14	Fetal mortality increased on day 11, reached 100% on day 12, and decreased thereafter. Limb and tail deformities were induced when 80 mg/kg was administered on day 13 and 14. Vertebral column deformities were induced when 80 mg/kg was administered on day 11.
	Single dose of 40	One of days 11 to 14	No teratogenic effect.

Results in Rabbits

Route	Doses (mg/kg)	Time of Administration During Gestation	Findings in the Offspring
Oral	17.5, 35, 70	Days 6 to 18	Significant increase in skeletal malformations occurred when 35 mg/kg was administered. All pregnant dams aborted between days 21 and 25 of gestation when 70 mg/kg was administered.
Intra-peritoneal	6.3, 12.5, 25	Days 7 to 16	Fetal mortality greatly increased at 12.5 mg/kg and reached 100% at 25 mg/kg. Skeletal defects and external malformations were induced when 12.5 mg/kg was administered. Their incidence was not statistically significant due to the low number of surviving fetuses.

No evidence of impaired fertility was observed in a study performed in male and female rats at oral dosages of up to 100 mg/kg/day.

In peri- and post-natal studies, rats received diltiazem in doses of 10, 30 or 100 mg/kg/day from day 14 of gestation through day 21 post-partum. Diltiazem was associated with a reduction in early individual weights and survival rates of the pups. At 100 mg/kg/day, dystocia was evident. Retinal and tongue malformations were more frequent in the offspring of the 30 and 100 mg/kg/day group.

BIBLIOGRAPHY

1. Bloedow D.C., Piepho R.W., Nies A.S., Gal J. Serum binding of diltiazem in humans. *J Clin Pharmacol* 1982; 22:201-205.
2. Bourassa M.G., Cote P., Theroux P., et al. Hemodynamics and coronary flow following diltiazem administration in anaesthetised dogs and in humans. *Chest* 1980; 78(suppl):224-230.
3. Dias V.C., Heywood J.T. I.V. diltiazem for paroxysmal supra-ventricular tachycardia (PSVT): a placebo-controlled study. *Circulation* 1991; 84:11-127 (Abstract).
4. Dias V.C., Weir S.J., Ellenbogen K.A. Pharmacokinetics and pharmacodynamics of intravenous diltiazem in patients with atrial fibrillation or atrial flutter. *Circulation* 1992; 86:1421-28.
5. Dougherty A., Jackman W.M., Naccarelli G.V., et al. Acute conversion of paroxysmal supra-ventricular tachycardia with intravenous diltiazem. *Am J Cardiol* 1992; 70:587-92.
6. Ellenbogen K., Dias V., Plumb V., et al. A placebo-controlled trial of continuous intravenous diltiazem infusion for 24-hour heart rate control during atrial fibrillation and atrial flutter: a multicenter study. *J Am Coll Cardiol* 1991; 18:891-7.
7. Hermann P., Rodger S.D., Remones G., Thenot J.P., London D.R., Morselli P.L. Pharmacokinetics of diltiazem after intravenous and oral administration. *Eur J Clin Pharmacol* 1983; 24:349-352.
8. Huycke E., Sung R., Dias V., et al. Intravenous diltiazem for termination of re-entrant supra-ventricular tachycardia: a placebo-controlled, randomised, double-blind multicentre study. *J Am Coll Cardiol* 1989; 13:538-44.
9. Kwong T.C., Sparks J.D., Peters P.T., Sparks C.E. Serum protein and lipoprotein binding of the calcium channel blocker diltiazem. *Clin Chem* 1984; 30:1031-1032.
10. Materne P., Legrand V., Vandormael M., et al. Hemodynamic effects of intravenous diltiazem with impaired left ventricular function. *Am J Cardiol* 1984; 54:733-737.
11. Mitchell L.B., Jutsy K.R., Lewis S.J., et al. Intracardiac electrophysiology study of intravenous diltiazem and combined diltiazem-digoxin in patients. *Am Heart J* 1982; 103:57-66.
12. Montamat S.C., Abermethy D.R. N-monodesmethyl diltiazem is the predominant metabolite of diltiazem in the plasma of young and elderly hypertensives. *Br J Clin Pharm* 1987; 24:185-189.
13. Rocha P., Baron B., Delestrain A., et al. Hemodynamic effects of intravenous diltiazem in patients treated chronically with propranolol. *Am I-emi J* 1986; 111:62-68.
14. Salerno D., Dias V., Kleiger R., et al. Efficacy and safety of intravenous diltiazem for treatment of atrial fibrillation and atrial flutter. *Am J Cardiol* 1989; 63: 1046-51.

15. Schwartz J.B., Abernethy D.R. Responses to intravenous and oral diltiazem in elderly and younger patients with systemic hypertension. *Am J Cardiol* 1987; 59:1111-1117.
16. Talajic M., Lemery R., Roy D., et al. Rate-dependent effects of diltiazem on human atrioventricular nodal properties. *Circulation* 1992; 86:870-77.
17. Cardizem Injectable Product Monograph, Crystaal, Division of Biovail Corporation, Control #065692, Date of Preparation: July 25, 2000.
18. Diltiazem Hydrochloride Injection Product Monograph, Sandoz Canada Inc., Control #100325, Date of Preparation: August 10, 2005.

Last Revised September 14, 2022